The electric vehicle drivetrain market is projected to expand from US$54.941 billion in 2024 to US$120.330 billion in 2029 at a CAGR of 16.98%. A drivetrain is a crucial vehicle component that translates power from the battery into motion. In an electric vehicle, the drivetrain c...

-
Segmentation of the Electric Vehicle Drivetrain Market
-
Key Players in the Electric Vehicle Drivetrain Market
- By Component
- Battery
- Controller
- Transmission
- Electric Motor
- By Type
- Front-wheel drive (FWD)
- Rear-Wheel Drive (RWD)
- All-Wheel Drive (AWD)
- Four-Wheel Drive (4WD)
- By Vehicle
- PHEV
- BEV
- FCEV
- HEV
- By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- UK
- Germany
- France
- Italy
- Others
- Middle East and Africa
- Saudi Arabia
- Israel
- Others
- Asia Pacific
- Japan
- China
- India
- South Korea
- Indonesia
- Thailand
- Others
- North America
- Electric Vehicle Battery Market Share
- EV Charging Connectors Market Report
- Electric Vehicle Tires Market Report
Need specialized data cuts or competitive intelligence?
Our analyst team provides bespoke market sizing, supplier audits, and country-level feasibility reports tailored to your enterprise roadmap.
Speak With an Industry Analyst →Ask an Industry Analyst
Have questions regarding this briefing or market projections? Inquire with our sector lead.
Related Press Releases
View All →
ADC Manufacturing & CDMO Market is expected to reach USD 10.49 billion by 2031
Aug 7, 2026
Lifestyle-Associated Cancer Epidemiology Market is expected to reach USD 13.12 billion by 2031
Aug 5, 2026
Psycho-Oncology Digital Health Market is anticipated to surpass USD 290.01 million in 2031 at a CAGR of 8.5%
Jul 30, 2026
Intratumoral Injection Therapy Market is expected to reach USD 630.39 million by 2031
Jul 24, 2026
Palliative Care in Oncology Market is expected to reach USD 244.1 billion by 2031
Jul 22, 2026More Press Releases
Oncology Drug Resistance Testing Market is projected to reach USD 3.41 billion in 2031 at a CAGR of 6.6 %
The oncology drug resistance testing market is expanding due to rising cancer prevalence, increasing drug resistance, and growing adoption of precision oncology. Advances in NGS-based testing, companion diagnostics, and targeted therapies, alongside FDA approvals and investments in personalized medicine, are accelerating demand for effective resistance monitoring across hospitals and clinical diagnostics worldwide.
TROP-2 Targeted Therapy Market is anticipated to surpass USD 3.29 billion in 2031 at a CAGR of 8.6 %
The TROP-2 Targeted Therapy market is expanding rapidly due to increasing precision oncology adoption, rising cancer prevalence, and growing use of antibody-drug conjugates. North America leads the market, while Asia Pacific shows the fastest growth. Continuous clinical trials, regulatory approvals, and strategic collaborations are accelerating innovation and commercial adoption worldwide.
Second Primary Cancer Prevention Market is expected to reach USD 24.7 billion by 2031
The Second primary cancer prevention refers to strategies aimed at reducing the risk of developing a new, unrelated cancer in individuals with a prior cancer diagnosis. Growing cancer survivorship, advances in treatment, and increasing awareness of long-term health outcomes have heightened the importance of prevention and surveillance programs. Key approaches include routine screening, genetic risk assessment, lifestyle modification, and long-term follow-up care. Government agencies and healthcare organisations increasingly emphasise survivorship care plans and evidence-based screening protocols to detect new malignancies at earlier stages. Continued investments in early detection technologies and personalised risk assessment are expected to support advancements in second primary cancer prevention.